MUTASI EGFR PADA PEMERIKSAAN SITOLOGI ADENOKARSINOMA PARU
Abstract
The case of lung cancer increased lately. World Health Organization (WHO) include lung cancer as one of the major problems facing the world in this decade, as more than 1.1 million people died from the disease. In histopathology, lung cancer is divided into several types, one of which is Adenocarcinoma. Various therapies developed to improve survival in patients with lung cancer, and recently also developed a therapeutic gene targets, one of which is the anti-EGFR. However, this therapy needs to be examination of the EGFR gene mutation, because the anti-EGFR therapy would respond in patients with EGFR gene mutation. This study aims to see how the pattern of EGFR mutations, and their relation to age, sex, and smoking habits. Research samples taken from pleural fluid cytology or biopsy of the tumor with fine needle aspiration, then examined whether there is an EGFR mutation. In this study, obtained 38 samples of patients with Adenocarcinoma of the lung, where 34% of patients had mutations in the gene EGFR, which consisted of 7 patients had mutations deletion in exon 19, 1 patients with mutations in exon 21L86IQ, 4 patients experienced EGFR mutations in exons 21L858R, and contained 1 those patients who had mutations in two places, namely in exon 19 and exon 21L861Q. EGFR mutations are many in the age range 40-49 years, but there is no relationship between the age of the patient with the presence and absence of mutations in the EGFR gene. In this study there was no difference between men and women who have EGFR mutations, but women with lung adenocarcinoma more mutated in EGFR. On this study, patients who did not smoke more EGFR mutations (51%) compared to the active smoking (10%).
Keywords: lung adenocarcinoma, EGFR mutations
Full Text:
PDFReferences
American Lung Association. State of Lung disease in diverse communities 2010; (online), (http://www.lung.org/assets/documents/publications/solddchapters/lc.pdf,.2014. diakses 6 Januari 2014)
Abdullah AA, Bujang N, Badril C, et al. The sensitivity and spesificity of a new scoring system using high resolution computed tomography to diagnose lung cancer. Medical Journal of Indonesia. 2009 ; 18: 179-86
Aisah AKN, Haryati, Bakhriansyah M. Profil penderita kanker paru primer di RSUD Ulin Banjarmasin tahun 2006-2011. Berkala Kedokteran. 2013; 9(2) : 169-80
Asih NGY, Effendy C. Keperawatan Medikal Bedah : Klien dengan Gangguan Sistem Pernafasan. Jakarta. 2003 : EGC
Ries L, Eisner M, Kosary C. Cancer Statistics Review. 2005 : 1975-2002. National Cancer Institute.
John TM. With Every Breath : A Lung Cancer Guidebook. The Lung Cancer Caring Ambassador’s Program. 2005
Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute. 2005 ; 97(5):339-46
Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, et al. Clinicopathologic Characteristics of EGFR Gene Mutation in Non Small Cell Lung Cancer. Journal of Thoracic Oncology. 2006 ; 1(3): 231-9
Chang QZ, Santos GC, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.2 Journal of Oncology. 2008 ; 26: 4268-75
Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non-Small Cell Lung Cancer. Journal of the National Cancer Institute. 2005 ; 97:643-55
Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival : A Meta-Analysis. Journal of the National Cancer Institute. 2013 ; 105: 595-605
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR Mutation and Resistance of Non-Small-Cell Lung to Gefitinib. The New England Journal of Medicine. 2005 ;352(8): 786-92
Haneda H, Sasaki H, Lindeman N, Kawano O, Endo K, Suzuki E, et al. A Correlation between EGFR Gene Mutation Status and Bronchoalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma. Jpn J Clin Oncology. 2006 ; 36(2):69-75
Fischer OM, Hart S, Gschwind A, Ulrich A. EGFR signal transactivation in Cancer Cells. Biochemical Society Transaction. 2003 ; 31(6):1203-7
Spano JP, Lagorce C, Atlan D, Milano G, Domonti J, Benamouzig R, et al. Impact of EGFR Expression on Colorectal Cancer Patient Prognosis and Survival. Annals of Oncology. 2005 ; 16:102-8
DOI: http://dx.doi.org/10.20527/jbk.v11i2.171
Article Metrics
Abstract view : 2306 timesPDF - 8773 times
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Jurnal Berkala Kedokteran
Indexed by :

This work is licensed under a Creative Commons Attribution 4.0 International License.





